Field Notes #14: Cannabis and Sleep, Still an Evidence Gap
Nine studies, 537 adults, and a very uncertain answer. A Cochrane review on cannabis for insomnia shows why feeling sleepy and treating insomnia need separate evidence.
Science, culture and capital — one dose at a time
A Cochrane review published on October 13 brings an awkwardly small evidence base to a familiar question: does medical cannabis help adults with insomnia? Its nine studies involved 537 adults. Most were small and lasted only a few weeks. The answer remains uncertain enough to resist both a sales pitch and a blanket dismissal. [1]
What the review found
The studies tested different products containing THC, CBD or both, delivered as oils, capsules or gel. Most compared them with placebo. These were not nine interchangeable tests of a single cannabis medicine. [1]
Across the studies, medical cannabis may have little or no clinically meaningful effect on sleep quality or satisfaction, total sleep time, and daytime functioning. A possible improvement in quality of life came with very uncertain evidence. The authors also found that cannabis may slightly increase adverse events; certainty for that finding was low. [1]
The outcomes did not all use the full 537-person sample. Sleep quality or satisfaction drew on seven studies with 374 people; total sleep time on six with 194; daytime functioning on five with 144. Those are different pools of evidence, not three separate ways of measuring every participant. [1]
The date matters
The review is new, but its latest search was April 5, 2025. That cutoff matters when someone presents an October 2026 publication as an assessment of every study available today. This is a synthesis of the evidence found by that search, not a live feed. [1]
Short follow-up, small samples and differences between products limit what the findings can tell us. Many studies also left out older adults or people with other health conditions. The review cannot settle how well treatment works over months or years, or how its balance of benefits and harms varies across the people who might use it. [1]
What patients deserve
A person reporting better sleep deserves to be heard. That experience can matter without establishing how reliably a particular product treats diagnosed insomnia. Feeling sleepy, sleeping longer and functioning better the next day are related questions, but they are not interchangeable outcomes.
For clinicians and researchers, the useful demand is more specific evidence: a defined formulation, a clear dose, enough participants and follow-up long enough to see whether any benefit lasts. The review's authors also call for more diverse study populations so the findings apply more fairly. [1]
For businesses, uncertainty should limit the claim. Neither the word cannabis nor the presence of CBD supplies the missing treatment evidence. This review is not a universal verdict on every formulation or every person's experience; it is a warning against sounding more certain than the trials allow.
The review reports no dedicated funding. This Field Note draws on Cochrane's public author summary and abstract, rather than an independent inspection of the full review's tables or complete declarations. [1]
The Last Word
The most useful finding may be how little evidence sits behind such a common treatment question. People with insomnia need better trials, not another argument about whether their experience counts.
— The Alkaloid
Sources
The Alkaloid publishes every Tuesday. Forward this to someone who needs the dose. Subscribe for full access: TheAlkaloid.com
